Medical Devices: Page 78
-
Edwards says it expects sales to stall in Q4 as hospital staff shortages stymie TAVR growth
The company has heard reports it may take hospitals “up to a year or two” to resolve the staffing situation.
By Nick Paul Taylor • Oct. 28, 2022 -
Getty Images
ResMed quarterly profit rises on AirSense sales; CEO skeptical about timeline of Philips’ return to market
CEO Mick Farrell says he’s “not optimistic” rival Philips will be back on the market in January “given all the issues that are there for them.”
By Nick Paul Taylor • Oct. 28, 2022 -
Explore the Trendline➔
Permission granted by Boston Scientific
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
Getty Images
Baxter lowers 2022 earnings forecast, citing supply chain, foreign-exchange pressures
The company took a $3.1 billion impairment charge in the third quarter related to its acquisition of connected care firm Hillrom in December 2021.
By Elise Reuter • Oct. 27, 2022 -
Courtesy of Baxter/Hillrom
Baxter warns hospitals to stop using connected incontinence pads over interference risk
The interference may affect insulin pumps, fetal monitors, telemetry devices, bladder scanners and infusion pumps.
By Nick Paul Taylor • Oct. 27, 2022 -
VCG / Stringer via Getty Images
Intuitive starts $1B accelerated stock repurchase, boosting recovery of share price
The move shows the robotic surgery maker “remains committed to returning cash to shareholders,” analysts said.
By Nick Paul Taylor • Oct. 27, 2022 -
Getty Images
Philips’ respirator recall troubles open door for rival ResMed, analysts say
Without a clear date for re-entering the market for sleep apnea devices, the company risks losing ground permanently to its competitor.
By Peter Green • Oct. 26, 2022 -
Spencer Platt/Getty via Getty Images
Medtech M&A decline poised to continue in 2023 amid ‘bumpy’ market: report
Dealmaking has dropped as companies grapple with surging inflation and decreased spending by hospitals, according to EY.
By Elise Reuter • Oct. 26, 2022 -
Boston Scientific exceeds Q3 revenue growth forecast on heart devices; profit sinks on R&D costs
Sales of the company's Watchman devices grew 26% in the period.
By Elise Reuter • Oct. 26, 2022 -
Sean Gallup via Getty Images
3M healthcare sales growth curbed in Q3 by hospital staffing shortages ahead of unit spinoff
The division remains set for a divestment in 2023 even as it struggles to gain momentum and sales slow on a drop in demand for surgical products.
By Nick Paul Taylor • Oct. 26, 2022 -
GE HealthCare revenue rose 6% in Q3 as supply chain woes ease
The medtech company says global healthcare spending is solid, particularly in Europe and Asia.
By Elise Reuter • Oct. 25, 2022 -
Courtesy of AlertWatch
BioIntelliSense buys AlertWatch, expanding Medtronic patient monitoring partnership
Medtronic will distribute AlertWatch to hospitals in the U.S. alongside BioIntelliSense’s wearable device for continuous remote monitoring.
By Nick Paul Taylor • Oct. 25, 2022 -
Sarah Silbiger via Getty Images
Accelerate Diagnostics withdraws BD-partnered device after FDA demands 510(k) clearance
An analyst said they were “somewhat surprised” by the FDA’s decision as “Arc does not directly lead to a patient result.”
By Nick Paul Taylor • Oct. 25, 2022 -
Courtesy of Medtronic
Medtronic’s planned spinoff ‘doesn’t move the needle’ in growth strategy: analysts
Combining patient monitoring and respiratory intervention businesses into a separate company may not be enough to address investor concerns.
By Elise Reuter • Oct. 24, 2022 -
Courtesy of Medtronic
Medtronic will spin out slower-growth patient monitoring, respiratory units to focus on core businesses
The segments will form a new connected care company, allowing Medtronic to invest more resources into faster-growing areas.
By Elise Reuter • Oct. 24, 2022 -
Permission granted by Philips
Philips to cut 4,000 jobs amid net loss related to recalls, declining sales
The layoffs will cost Philips $300 million over the coming quarters and save it about the same amount annually thereafter.
By Nick Paul Taylor • Oct. 24, 2022 -
Courtesy of Boston Scientific
Boston Scientific, Edwards set to report Q3 results after ‘encouraging start’ to medtech earnings season
The companies may post results that show procedure volumes are recovering, analysts say.
By Nick Paul Taylor • Oct. 24, 2022 -
Permission granted by Philips
New Philips CEO Jakobs apologizes for handling of sleep apnea device recall
In a blog post, the executive says he’s “deeply sorry” for chaotic recall of faulty respirators.
By Peter Green • Oct. 21, 2022 -
Courtesy of Abiomed
Abiomed wraps up Impella post-approval studies requested by FDA
Abiomed’s studies linked the device to a 22% to 45% improvement in the volume of blood pumped after 90 days, suggesting it’s a viable alternative to balloon therapy.
By Nick Paul Taylor • Oct. 21, 2022 -
Getty Images
FDA moves to make effect on health equity part of breakthrough device considerations
If it finalizes the proposal, the agency will expand its breakthrough program to devices that improve accessibility.
By Nick Paul Taylor • Oct. 21, 2022 -
Courtesy of Abbott
Abbott Q3 device sales slowed by supply chain pressures; COVID-19 tests exceed expectations
The company raised its earnings forecast for 2022 on the back of an expected $7.8 billion in annual sales related to COVID-19 testing.
By Elise Reuter • Oct. 19, 2022 -
Courtesy of Magnolia
BD forms co-promotion pact with Magnolia to reduce blood culture contamination
Magnolia’s blood collection device diverts the first 1.5 to 2 milliliters of blood samples that may be contaminated with flecks of skin, paving the way for more accurate diagnosis of sepsis.
By Nick Paul Taylor • Oct. 19, 2022 -
Sarah Silbiger via Getty Images
FDA seeks feedback on plans to draft and finalize medical device guidance in 2023
The agency’s review includes guidance on transitioning away from emergency use authorizations, while abandoning plans for guidance on software as a medical device.
By Nick Paul Taylor • Oct. 19, 2022 -
Courtesy of MedAlliance
Cordis to spend $235M to buy Swiss maker of alternative to paclitaxel balloons
As regulatory and sales milestones are hit, Cordis could pay up to $900 million in total.
By Nick Paul Taylor • Oct. 19, 2022 -
Courtesy of Intuitive Surgical
Intuitive’s robotic surgery volumes recovered in Q3; shares climb
As hospital staffing increased and COVID-19 wariness eased, the number of procedures performed with the company’s hallmark da Vinci system rose 20% in the third quarter from a year earlier.
By Peter Green • Oct. 18, 2022 -
Mario Tama via Getty Images
J&J touts rising procedure volumes, lowers full-year forecast on foreign-exchange concerns
Analysts said the results were an “encouraging start” to medtech earnings for the third quarter.
By Elise Reuter • Oct. 18, 2022
Previous
